H. Pylori Eradication With Argon Plasma During Endoscopy

Launched by CHRISTOPHER C. THOMPSON, MD, MSC · Jul 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat Helicobacter pylori (H. pylori) infections, which can cause stomach issues. The researchers are testing a special technique called argon plasma therapy (HEAPE) that uses a gas to help kill the bacteria during an endoscopy, a procedure where doctors look inside the stomach using a thin tube. The trial aims to see if this method can effectively reduce H. pylori levels with fewer side effects compared to traditional treatments.

To be eligible for the trial, participants must be at least 18 years old, have a confirmed H. pylori infection that hasn’t been treated yet, and be scheduled for an upper endoscopy. They should also be able to understand and sign consent forms. During the study, patients will receive the HEAPE treatment and then take antibiotics as usual. Researchers will check the effectiveness of the treatment before and after it using a simple breath test. This trial is designed to explore the safety and effectiveness of this new treatment approach, and participation may help improve how H. pylori infections are managed in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects must be 18 years or older
• • 2. Confirmed untreated H. pylori infection
• • 3. Able to understand and sign informed consent
• • 4. Available to return for all routine follow-up study visits
• • 5. Patients should have upper endoscopy scheduled according to latest guidelines, e.g., as a part of their diagnostic work-up of HP positive test, regardless of their decision to participate in the study.
• Exclusion Criteria:
• • 1. Patients actively undergoing H.pylori eradication therapy treatment with antibiotics or proton pump inhibitors (PPIs) two weeks prior to the HEAPE procedure.
• • 2. Pregnancy or puerperium
• • 3. Severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)
• • 4. Lactation
• • 5. An inability to provide informed consent
• • 6. Any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study.
• • 7. Hernias / aspiration risk